Logo 1 Logo 2

Investigational Drug Details

Drug ID: D244
Drug Name: Perphenazine
Synonyms:
Type: small molecule
DrugBank ID: DB00850
DrugBank Description: An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine.
PubChem ID: 4748
CasNo: 58-39-9
Repositioning for NAFLD: Yes
SMILES: OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
Structure:
InChiKey: RGCVKNLCSQQDEP-UHFFFAOYSA-N
Molecular Weight: 403.969
DrugBank Targets: Dopamine D2 receptor; Dopamine D1 receptor; Calmodulin
DrugBank MoA: Binds to the dopamine D1 and dopamine D2 receptors and inhibits their activity. The mechanism of the anti-emetic effect is due predominantly to blockage of the dopamine D2 neurotransmitter receptors in the chemoreceptor trigger zone and vomiting centre. Perphenazine also binds the alpha andrenergic receptor. This receptor's action is mediated by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
DrugBank Pharmacology: Perphenazine is a piperazinyl phenothiazine, acts on the central nervous system, and has a greater behavioral potency than other phenothiazine derivatives whose side chains do not contain a piperazine moiety. It is a member of a class of drugs called phenothiazines, which are dopamine D1/D2 receptor antagonists. Perphenazine is 10 to 15 times as potent as chlorpromazine; that means perphenazine is a highly potent antipsychotic. In equivalent doses it has approximately the same frequency and severity of early and late extrapypramidal side-effects compared to Haloperidol.
DrugBank Indication: For use in the management of the manifestations of psychotic disorders and for the control of severe nausea and vomiting in adults.
Targets:
Therapeutic Category:
Clinical Trial Progress:
Latest Progress: